Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials is a research paper published in PLoS Pathogens (2023). On theSindex it has a DataRank of 0. It has been cited 56 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068614
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068635
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068618
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068619
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068613
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068617
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: P30 AI027757
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: R01 AI152115
South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation
Grant: 98341
Bill & Melinda Gates Foundation’s Collaboration for AIDS Vaccine Discovery
Grant: 1032144
NIAID NIH HHS
Grant: UM1 AI069436
NIAID NIH HHS
Grant: U01 AI069436
National Institutes of Health
Grant: 3P30AI027757-36S1
University of Washington/Fred Hutch Center for AIDS Research
National Institutes of Health
Grant: 5R01AI152115-05
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa
National Institutes of Health
Grant: 5UM1AI068613-16
LC: HIV PREVENTION TRIALS NETWORK
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 5UM1AI068619-09
LOC: HIV Prevention Trials Network
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 3UM1AI068617-20S1
HPTN SDMC: HPTN 096 Getting to Zero among Highest HIV Incidence (HHI) Men who have Sex with Men (MSM) in the American South: Testing an Integrated Strategy
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
FWCI
6.86
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals